RU2020121363A3 - - Google Patents

Download PDF

Info

Publication number
RU2020121363A3
RU2020121363A3 RU2020121363A RU2020121363A RU2020121363A3 RU 2020121363 A3 RU2020121363 A3 RU 2020121363A3 RU 2020121363 A RU2020121363 A RU 2020121363A RU 2020121363 A RU2020121363 A RU 2020121363A RU 2020121363 A3 RU2020121363 A3 RU 2020121363A3
Authority
RU
Russia
Application number
RU2020121363A
Other languages
Russian (ru)
Other versions
RU2020121363A (en
RU2774928C2 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority claimed from RU2020121363A external-priority patent/RU2774928C2/en
Priority to RU2020121363A priority Critical patent/RU2774928C2/en
Priority to MA58653A priority patent/MA58653B1/en
Priority to BR112022026356A priority patent/BR112022026356A2/en
Priority to PCT/RU2021/050170 priority patent/WO2021262040A1/en
Priority to CN202180044905.7A priority patent/CN115803026A/en
Publication of RU2020121363A publication Critical patent/RU2020121363A/en
Publication of RU2020121363A3 publication Critical patent/RU2020121363A3/ru
Publication of RU2774928C2 publication Critical patent/RU2774928C2/en
Application granted granted Critical
Priority to CL2022003725A priority patent/CL2022003725A1/en
Priority to CONC2023/0000604A priority patent/CO2023000604A2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
RU2020121363A 2020-06-26 2020-06-26 Use of glutarimide derivative for therapy of diseases associated with aberrant activity of interleukin-6 RU2774928C2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
RU2020121363A RU2774928C2 (en) 2020-06-26 Use of glutarimide derivative for therapy of diseases associated with aberrant activity of interleukin-6
CN202180044905.7A CN115803026A (en) 2020-06-26 2021-06-18 Use of glutarimide derivatives for the treatment of diseases associated with abnormal interleukin-6 activity
BR112022026356A BR112022026356A2 (en) 2020-06-26 2021-06-18 USE OF A GLUTARIMIDE DERIVATIVE TO TREAT DISEASES ASSOCIATED WITH ABERRANT INTERLEUKIN-6 ACTIVITY
PCT/RU2021/050170 WO2021262040A1 (en) 2020-06-26 2021-06-18 Use of a glutarimide derivative for treating diseases associated with aberrant interleukin-6 activity
MA58653A MA58653B1 (en) 2020-06-26 2021-06-18 USE OF A GLUTARIMIDE DERIVATIVE TO TREAT DISEASES RELATED TO ABERRANT INTERLEUKIN-6 ACTIVITY
CL2022003725A CL2022003725A1 (en) 2020-06-26 2022-12-22 Use of a glutarimide derivative for the treatment of diseases associated with aberrant interleukin-6 activity.
CONC2023/0000604A CO2023000604A2 (en) 2020-06-26 2023-01-19 Use of a glutarimide derivative for the treatment of diseases associated with aberrant interleukin-6 activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2020121363A RU2774928C2 (en) 2020-06-26 Use of glutarimide derivative for therapy of diseases associated with aberrant activity of interleukin-6

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2022116762A Division RU2022116762A (en) 2022-06-22 USE OF GLUTARIMIDE DERIVATIVE FOR THE THERAPY OF DISEASES ASSOCIATED WITH ABERRANT ACTIVITY OF INTERLEUKIN-6

Publications (3)

Publication Number Publication Date
RU2020121363A RU2020121363A (en) 2021-12-27
RU2020121363A3 true RU2020121363A3 (en) 2021-12-27
RU2774928C2 RU2774928C2 (en) 2022-06-27

Family

ID=

Also Published As

Publication number Publication date
MA58653A1 (en) 2023-07-31
BR112022026356A2 (en) 2023-01-17
CL2022003725A1 (en) 2023-05-19
RU2020121363A (en) 2021-12-27
MA58653B1 (en) 2024-02-29
WO2021262040A1 (en) 2021-12-30
CO2023000604A2 (en) 2023-01-26
CN115803026A (en) 2023-03-14

Similar Documents

Publication Publication Date Title
BR112023005462A2 (en)
BR112021014123A2 (en)
BR112023012656A2 (en)
BR112022024743A2 (en)
BR102021018859A2 (en)
BR112022009896A2 (en)
BR102021007058A2 (en)
BR102020022030A2 (en)
BR112023011738A2 (en)
BR112023016292A2 (en)
BR112023004146A2 (en)
BR112023011539A2 (en)
BR112023011610A2 (en)
BR112023008976A2 (en)
BR112023009656A2 (en)
BR112023006729A2 (en)
BR102021020147A2 (en)
BR102021018926A2 (en)
BR112021017747A2 (en)
BR102021012107A2 (en)
BR102021012003A2 (en)
BR112021013417A2 (en)
BR102021010467A2 (en)
BR102021009555A2 (en)
BR102021009475A2 (en)